Dry Age-related Macular Degeneration, Geographic Atrophy, Gene Therapy, Intravitreal Injection
Conditions
Brief summary
Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham injection. All enrolled subjects will be followed for 24 months to evaluate reduction in GA growth and safety of intravitreal AAVCAGsCD59.
Interventions
BIOLOGICALIntravitreal AAVCAGsCD59
AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
OTHERIntravitreal Sham Injection
Sham injection mimics a real injection in the enrolled eye
Sponsors
Hemera Biosciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Intervention model description
Subjects will be assigned to low dose AAVCAGsCD59, high dose AAVCAGsCD59, or sham arm.
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Advanced dry AMD with GA in the study eye 2. BCVA in the study eye of 80 or less ETDRS letters (Snellen equivalent 20/25 or worse) 3. Total cumulative GA lesion size 2.5 mm2 to 12.5 mm2 in the study eye as confirmed by the reading center during the Screening Period.
Exclusion criteria
1. GA secondary to non-AMD etiologies in the study eye (i.e. myopia, inherited retinal diseases). 2. GA associated with the presence of an RPE rip. 3. GA contiguous with peripapillary atrophy. 4. Active CNV secondary to wet AMD in the study eye and currently receiving anti-VEGF ocular treatment within the previous 18 months. 5. Subretinal fibrosis in the macula from CNV both clinically and imaged on SD-OCT in the macula. 6. Previous macular laser photocoagulation (i.e. focal or grid laser for macular edema), photodynamic therapy (PDT), ocular/orbital radiation, laser to CNV, or subretinal surgery for CNV in the study eye. 7. History of conditions in the study eye which might alter visual acuity or interfere with study testing including proliferative diabetic retinopathy (PDR), clinically significant macular edema (CSME), central retinal vein occlusion (CRVO), hemi retinal vein occlusion (HRVO), macular branch retinal vein occlusion, and optic neuropathy. 8. Active uncontrolled glaucoma with at least one of the following: IOP\>30 mmHg despite maximum medical treatment with glaucoma medications, cup-to-disc ratio of \>0.9, visual field defects secondary to glaucoma that involve the macula, or optic atrophy from glaucoma. 9. Active acute or chronic infectious uveitis, retinitis, or conjunctivitis (excluding blepharitis)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the change in Geographic Atrophy area (mm2) measured at Day 0 and compared to the measurement at Month 24 | 24 Months | Geographic atrophy will be measured based on imaging of the retina |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of conversion from dry to wet age-related macular degeneration | 24 Months | Measure the number of treated eyes in the sham and AAVCAGsCD59-treated arms that convert from dry to wet age-related macular degeneration |
| Change in visual acuity of the AAVCAGsCD59 treated eye | 24 Months | Visual acuity measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart will be compared at Day 0 and Month 24 |
Outcome results
None listed